Business
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
Clinical utility study findings based on analysis of the National Cancer Institute’s SEER database SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte,
About this update from Veracyte, Inc.
[{"type":"text","content":"\nClinical utility study findings based on analysis of the National Cancer Institute’s SEER database\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized treatment approaches for men with prostate cancer. The study utilized data from the first linkage of prostate cancer cases reported by central cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) Program, with Decipher test results. SEER is a population-based cancer registry supported by the National Cancer Institute (NCI). The findings appear online in JNCI Cancer Spectrum.\n\n\nIn the U.S., an estimated 288,300 men are expected to be diagnosed with prostate cancer in 2023 and 34,700 men are expected to die from the disease.[1] Treatment for prostate cancer is primarily selected based on clinical risk factors such as Gleason score, clinical stage and prostate-specific antigen (PSA). Clinical factors alone, however, do not always reflect the true biology of the tumor, which can lead to over- or under-treatment of patients with prostate cancer. The Decipher Prostate test molecularly assesses the likelihood of a patient’s cancer metastasizing within the next five years. Armed with this information, a physician can recommend tailored treatment plans, including no treatment, less intensive treatment or earlier, more intensive interventions.\n\n\n\"Validation from multiple randomized trials has consistently demonstrated the prognostic performance of the Decipher 22-gene expression test,” said Daniel Spratt, M.D., chair of the Department of Radiation Oncology at UH Cleveland Medical Center. “This study builds upon this with real-world data of how the test is being used in a population sample and demonstrates how we are moving toward the goal of personalized therapy. Patients with a low Decipher score, indicating a better prognosis, can be guided towards treatment de-escalation, and those with higher Decipher scores, indicating a worse prognosis, can be guided towards appropriate treatment.”\n\n\nThe study analyzed data from 8,297 patients in the SEER registry who received a primary prostate cancer diagnosis from 2010 to 2018 and underwent Decipher Prostate testing. Researchers ev...